Elephas
  • about
    • leadership
    • investors
    • board of directors
  • join
  • biopharma services
  • powered by cybrid™
  • clinical trials
  • contact
  • news & resources
    • press releases
    • media
    • posters
    • publications
women medical professional talking with patient
women medical professional talking with patient

cybrid-cropped

Driving Change Through Live Tumor Interrogation and Imaging

Cybrid™ is the revolutionary live tumor diagnostic platform that powers Elephas’ Biopharma Service offerings. Its unique process and proprietary instruments bring a new dimension of capabilities and insights to analysis of response to oncology therapies. No platform can provide this distinct combination of capabilities:

LIVE TUMOR FRAGMENTS (LTFs)™

Live Tumor Fragments (LTFs)™ are taken directly from a patient, maintaining the tumor architecture and tumor microenvironment.

Sample-Tumor3

A core needle is inserted into the tumor

Tumor in needle

The live tumor section is taken from the core needle

cybrid primary full color logo

Cybrid™ fragments, sorts and interrogates the live tumor fragments (LTFs)™

slicing

The tumor microenvironment and architecture including immune and support cells/structures remain intact in the LTFs™

3D Spatial Imaging & Multiphoton Microscopy

Cybrid™ allows for minimally destructive, time course monitoring of tumor cells with label and label-free imaging in 3D spatial imaging with multiphoton microscopy.

HubSpot Video

Cybrid™ incorporates a comprehensive suite of assays to help understand the mechanisms of action of immunotherapeutic agents indicating drug response.

Secretome profiling • Cellular markers • Transcriptomics • Spatial biology

A cloud-based portal, CybridView™ offers frictionless access to results and data from studies run through the Cybrid™ platform. Results are available within two weeks* of the study completion with dynamic visualization for analysis of multiomic assays and images.

 

*<20 patient samples, time from receipt of test article

Laptops with cybrid view logo

Frequently Asked Questions

Why use live tumor fragments (LTFs) over spheroids or organoids?

LTFs derived from tumor biopsies retain the native architecture and microenvironment of the parental tumor, including immune cells, which are required to predict response to immunotherapy.

Unlike spheroids or organoids, there is no requirement for the expansion of cells or reconstitution of immune cells, enabling a faster turnaround time to characterize the MOA and/or efficacy of candidate therapeutics.

Additionally, precision fragmentation of tumor biopsies eliminates the need for non-specific enzymatic dissociation of tumor tissue, which can disrupt/alter the native tumor architecture.

What is Elephas’ advantage of using multiphoton imaging over conventional techniques?

Conventional techniques such as confocal microscopy can be destructive and have limited penetration into the tissue sample.

Elephas’ multiphoton imaging is non-destructive, enables real-time monitoring of immune cells, and allows label-free imaging at significantly higher penetration depths to investigate LTFs in 3D.

What is the benefit of combining multiphoton imaging and multiplexed assays to predict treatment response?

Multiplexed assays are routinely used to profile cell markers, cytokines, chemokines, and mRNA expression to determine response to drugs. However, these assays are typically performed in the absence of spatial context

By combining various assessments with multiphoton imaging, we can analyze spatial and temporal information at single cell resolution to understand the impact of drugs on cell-cell interactions, cell morphology, and the arrangement of cells in LTFs over time.

The combination of these techniques also generates a rich and diverse dataset that can be used to train AI algorithms to predict response to different therapies.

  • about
  • biopharma services
  • powered by cybrid™
  • clinical trials
  • news & resources
  • leadership
  • contact
  • privacy policies
Follow us on
© 2023 Elephas - All rights reserved